• Outlook Therapeutics set new executive compensation tied to a near-term FDA decision on ONS-5010 (bevacizumab-vikg).
• Granted stock options on July 21, 2026: CEO Robert C. Jahr 100,000 options; CFO Lawrence A. Kenyon 210,078 options.
• Options carry a $1.43 exercise price; vest July 21, 2027, contingent on continued service.
• Authorized cash bonuses of $420,000 for Jahr, $200,000 for Kenyon, payable only if FDA approval occurs by July 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-086406), on July 24, 2026, and is solely responsible for the information contained therein.